Novel Vaccine Products for Planned Phase I Immunogenicity Studies in Infants
|
|
|
- Clement Pope
- 6 years ago
- Views:
Transcription
1 Office of AIDS Research Novel Vaccine Products for Planned Phase I Immunogenicity Studies in Infants L. Jean Patterson, PhD Office of AIDS Research, NIH February 7, 2017
2 Office of AIDS Research OAR Responsibilities -Coordinate the scientific, budgetary, legislative, and policy elements of NIH HIV/AIDS research. -Develop a strategic plan as a roadmap for allocation of funds -Receive and disperse across NIH all funds for HIV/AIDS research -Ensure that research dollars are invested in the highest priority areas of scientific opportunity in the global fight against HIV/AIDS
3 Office of AIDS Research Overarching High Priority Areas Reduce the Incidence of HIV/AIDS Next Generation HIV Therapies Research Toward a Cure HIV-Associated Comorbidities, Complications, & Coinfections Less Toxic and Longer Lasting Treatment Basic Research, Health Disparities, Behavioral & Social Sciences, and Training Optimize Engagement and Retention
4 Office of AIDS Research IMPAACT Network Vaccine Task Force Outcomes -Immune responses to candidate vaccines have been shown to be of higher magnitude and durability in infants compared to adults. -Immune modulation in infancy and childhood may enhance the efficacy of products administered later in life. Gaps exist in our understanding of infant immunity.
5 Office of AIDS Research IMPAACT Vaccine Task Force Outcomes-cont. 3 recommendations: -Known surrogates of immune protection in pediatric cohorts could and should be studied using existing samples. -Efficacy studies are not feasible at this time within IMPAACT. -However, a Vaccine Working Group soon will be established to develop and implement a rolling protocol design within a 3-year timeframe to evaluate safety and immunogenicity of multiple candidate HIV vaccine products and other agents/products to prevent HIV transmission.
6 Office of AIDS Research Criteria for selection of candidate vaccine products Must be: Unencumbered by Industry/Pharma partners Already tested or soon to enter Phase I clinical trial in adults GMP product on the shelf or ready in the next 6-12 months Enough available product for infant studies
7 Overall Summary of Available Products 1. DNA/Protein: PDPHV (HVTN protocol 124) Shan Lu, UMass 2. CH505 Envelope Clade C Gp120 lineage design proteins; T/F, Wk 53, 78, 100 envelopes (HVTN 115 enrolling soon) Bart Haynes, Duke 3. Env proteins: -BG505 SOSIP Gp140 trimer, developed from a Clade A, infant T/F virus (planned as part of an HVTN adjuvants trial) John Moore, Cornell -Gp145 trimeric Clade C envelope, DAIDS/MHRP -Gp140 fold-on trimer, Clade C envelope, MHRP
8 Overall Summary of Available Products 1. DNA/Protein: PDPHV (HVTN protocol 124) Shan Lu, UMass 2. CH505 Envelope Clade C Gp120 lineage design proteins; T/F, Wk 53, 78, 100 envelopes (HVTN 115 enrolling soon) Bart Haynes, Duke 3. Env proteins: -BG505 SOSIP Gp140 trimer, developed from a Clade A, infant T/F virus (planned as part of an HVTN adjuvants trial) John Moore, Cornell -Gp145 trimeric Clade C envelope, DAIDS/MHRP -Gp140 fold-on trimer, Clade C envelope, MHRP
9 Office of AIDS Research A. DNA/Protein prime-boost or co-immunization DNA prime/protein boost using multigene polyvalent HIV vaccine (DP6-001 clinical trial) Shan Lu, UMass -6 DNA plasmids encoding gp120 genes from primary HIV envelopes; clades A, B(2), C, E, and gag gene from clade C subtype -5 Gp120 proteins matching same clades as DNA formulated in QS21 -Healthy volunteers were enrolled in Phase I trial at UMMS -DNA (ID or IM) at Wk 0, 4, 12; protein boosts (IM) at Wk 20, 28, IM
10 High level Env-Specific Serum IgG Responses in DP6-001 Vaccinees (quickly rising to the level of level following a single protein boost) gp120 specific IgG titers gp120 specific IgG titers (log 10 ) Group A (DNA-ID x 3 + protein x 2) Group B (DNA-IM x 3 + protein x 2) gp120 specific IgG titers Weeks g p s p e c ific a n tib o d y r e s p o n s e in D P v a c cweeks in e e g p s p e c ific Ig G tite r s G ro u p A G ro u p B W e e k Long lasting IgG titers for the study period Wang, S., et. al. Vaccine, 2008
11 A panel of human mabs with potent and cross reactive (against 3-4 subtypes) ADCC and ADCP activities from DP6-001 volunteers Matthew R. Costa et al. J. Virol. 2016;90:
12 PDPHV (HVTN protocol 124) PD (DNA vaccines produced from E coli) gp120-a, gp120-b, gp120-c, gp120-ae, Gag-C 0.4 mg each for a total of 2 mg at each immunization IM injection PP (protein vaccines produced from CHO) gp120-a, gp120-b, gp120-c, gp120-ae 100 mcg each for a total of 400 mcg at each immunization Adjuvant GLA-SE (from IDRI) Two possible immunization schedules Sequential: DNA: months 0, 2, 4 and protein months 6, 8 Simultaneous: DNA + protein: months 0, 2, 4, 6, 8 Shan Lu, UMass
13 Infant versus adults rhesus macaques immunized with DNA prime-rad5 VRC vaccine more evidence that DNA priming elicits high titered antibodies VRC DNA prime-rad5 boost regimes in HVTN505 adult macaques infant macaques Vincent Han, Sallie Permar, Koen Von Rompay, Bart Haynes
14 Study Summary When using DNA as a priming immunogen, infant rhesus macaques responded better than adult rhesus macaques with regard to binding and neutralizing antibody induction.
15 Overall Summary of Available Products 1. DNA/Protein: PDPHV (HVTN protocol 124) Shan Lu, UMass 2. CH505 Envelope Clade C Gp120 lineage design proteins; T/F, Wk 53, 78, 100 envelopes (HVTN 115 enrolling soon) Bart Haynes, Duke 3. Env proteins: -BG505 SOSIP Gp140 trimer, developed from a Clade A, infant T/F virus (planned as part of an HVTN adjuvants trial) John Moore, Cornell -Gp145 trimeric Clade C envelope, DAIDS/MHRP -Gp140 fold-on trimer, Clade C envelope, MHRP
16 Office of AIDS Research B. Envelope proteins lineage design CH505 Envelope Clade C Gp120 proteins; T/F, Wk 53, 78, 100 envelopes (HVTN 115 enrolling soon) Bart Haynes, Duke -Isolated over time in an individual who went on develop broadly neutralizing antibodies - Liao, et. al., Nature, Envs selected coincided with emergence of lineages able to develop into bnabs -Need to re-purify Wk 53 protein before use as immunogen -May see accelerated development of bnabs in infants -Plan to use GLA-SE adjuvant (IDRI) in adult trial -Sallie Permar proposal to IMPAACT (CAP523)
17 Overall Summary of Available Products 1. DNA/Protein: PDPHV (HVTN protocol 124) Shan Lu, UMass 2. CH505 Envelope Clade C Gp120 lineage design proteins; T/F, Wk 53, 78, 100 envelopes (HVTN 115 enrolling soon) Bart Haynes, Duke 3. Env proteins: -BG505 SOSIP Gp140 trimer, developed from a Clade A, infant T/F virus (planned as part of an HVTN adjuvants trial) John Moore, Cornell -Gp145 trimeric Clade C envelope, DAIDS/MHRP -Gp140 fold-on trimer, Clade C envelope, MHRP
18 Office of AIDS Research C. Envelope proteins as part of a boosting strategy or alone BG505 SOSIP Gp140 trimer, developed from a Clade A, infant T/F virus (planned as part of an HVTN adjuvants trial) John Moore, Cornell -In rabbits and NHPs, elicits high titered homologous Tier 2 neutralizing antibodies, but unfortunately not Tier 2 heterologous neuts, which are desired -Later, more stabilized versions of this trimer have been developed in the laboratory, known to elicit fewer anti-v3 antibodies and presumably better Tier 2 neutralizing antibodies - Use as a boosting immunogen in future strategies Sanders, et. al., J. Virol. 2002; Sanders, et. al., Plos Pathogens 2013; de Taeye, et. al., Cell 2015
19 Vaccination of neonates with soluble CH505 near-native SOSIP trimers Study goal: To determine whether the neonate antibody repertoire can recognize bnab epitopes on HIV-1 Env with trimer vaccination. Env TF TF TF w53 w78 w100 Timept (week) Adults N=4 Neonates Infants **Some data after week 20 are still pending for adults N=3
20 Summary CH505 chimeric trimer vaccination of infants elicited higher binding, CD4 blocking, as well as tier 1 neutralizing antibodies. Studies are underway with stabilized chimeric CH505 sequential trimers with the V3 loop and the gp41 unexposed to compare immunogenicity of closed trimers versus open trimers in infants.
21 Overall Summary of Available Products 1. DNA/Protein: PDPHV (HVTN protocol 124) Shan Lu, UMass 2. CH505 Envelope Clade C Gp120 lineage design proteins; T/F, Wk 53, 78, 100 envelopes (HVTN 115 enrolling soon) Bart Haynes, Duke 3. Env proteins: -BG505 SOSIP Gp140 trimer, developed from a Clade A, infant T/F virus (planned as part of an HVTN adjuvants trial) John Moore, Cornell -Gp145 trimeric Clade C envelope, DAIDS/MHRP -Gp140 fold-on trimer, Clade C envelope, MHRP
22 Office of AIDS Research C. Envelope proteins as part of a boosting strategy or alone cont. Gp145 trimeric Clade C envelope DAIDS/MHRP -Was intended as a boost protein for the replicating Tian Tian vaccine in China, but unsure of status of this trial Gp140 fold-on trimer, Clade C envelope MHRP -Not native-like, but has been in adults as a boost for the APPROACH study
23 Office of AIDS Research D. Longer shot candidates -CE p24 DNA prime/p55 Gag DNA IL-12 boost and/or boost with available Envelope protein (Mullins) Q Clade B Gp120 envelope protein (BG ) (Haynes) Q Chimp AdC6/C7 Clade C Gp120 (Ertl) - TBD -ChAdOx1 + HIV consv6 (Hanke) TBD -mrna - TBD
24 Office of AIDS Research Acknowledgements OAR, OD IMPAACT BioQual Maureen Goodenow Sharon Nachman Mark Lewis Peter Kim John Sleasman Bonnie Mathieson Duke UC Davis DAIDS, NIAID Barton Haynes Koen Von Rompay Mary Marovich Sallie Permar Kevin Ryan Vincent Han Michael Pensiero Kevin Saunders Sheryl Zwerski David Montefiori Carl Dieffenbach Rob Parks UMass Shan Lu Beth Israel Deaconess Medical Center Sampa Santra
25 NIH Turning Discovery Into Health 30
Virus Panels for Assessing Vaccine-Elicited Neutralizing Antibodies
Virus Panels for Assessing Vaccine-Elicited Neutralizing Antibodies Michael Seaman, Ph.D. Center for Virology and Vaccine Research Beth Israel Deaconess Medical Center Harvard Medical School J. Virol.
Recombinant Baculovirus Derived HIV-1 Virus-Like Particles Elicit Potent Neutralizing Antibody Responses
Recombinant Baculovirus Derived HIV-1 Virus-Like Particles Elicit Potent Neutralizing Antibody Responses Weimin Liu University of Alabama at Birmingham Introduction and Rationale Virus-like particles (VLPs)
Progress in HIV Vaccine Development Magdalena Sobieszczyk, MD, MPH. Division of Infectious Diseases Columbia University Medical Center
Progress in HIV Vaccine Development Magdalena Sobieszczyk, MD, MPH Division of Infectious Diseases Columbia University Medical Center 1 Outline A short history of HIV vaccine design and development Describe
FUNDERS UPDATE- BMGF. Third HIV Env Manufacturing Workshop Sponsored by DAIDS-NIAID-NIH and the HIV Global Vaccine Enterprise July 20-21, 2017
FUNDERS UPDATE- BMGF Third HIV Env Manufacturing Workshop Sponsored by DAIDS-NIAID-NIH and the HIV Global Vaccine Enterprise July 20-21, 2017 Susan Barnett Senior Program Officer, Product and Clinical
June 11, 2015 Michael Pensiero, VTRB A workshop sponsored by the Division of AIDS and the Global HIV Vaccine Enterprise
HIV Envelope Manufacturing Workshop June 11, 2015 Michael Pensiero, VTRB A workshop sponsored by the Division of AIDS and the Global HIV Vaccine Enterprise Presentation Outline HIV Env Protein Manufacturing
SAMRC S RESPONSE TO HIV & TB: WALKING THE TALK: MOVING TO CONTROL
SAMRC S RESPONSE TO HIV & TB: WALKING THE TALK: MOVING TO CONTROL Glenda Gray President & CEO SAMRC 1 SA AIDS 2017 Durban 15 June 2017 Partner logo LEADERSHIP IN A TIME OF UNCERTAINTY 2 BASELINE BUDGET
HVTN P5 Vaccine Trials
HVTN P5 Vaccine Trials Erica Andersen-Nissen, PhD Director, Cape Town HVTN Immunology Laboratory Considerations for a Pan-African HIV Vaccine Development Agenda Kigali, Rwanda 16-17 March 2015 HVTN Mission
Higher priming doses enhance HIV-specific humoral but not cellular. responses in a randomized, double-blind phase Ib clinical trial of
Higher priming doses enhance HIV-specific humoral but not cellular responses in a randomized, double-blind phase Ib clinical trial of preventive HIV-1 vaccines Pierre-Alexandre Bart a,b, Yunda Huang c,
The Kitchen Sink. Glenda Gray AIDS vaccine at the cross roads: how to adapt to a new preven9on age? Monday 7 th October, 2013, Barcelona
The Kitchen Sink Glenda Gray AIDS vaccine at the cross roads: how to adapt to a new preven9on age? Monday 7 th October, 2013, Barcelona The only important slide of my presentation. All efficacy trial in
Lynn Morris. "Plan B"- bnabs for HIV prevention
"Plan B"- bnabs for HIV prevention Lynn Morris National Institute for Communicable Diseases, a division of the National Health Laboratory Service (NHLS) of South Africa, University of the Witwatersrand,
Novel Heterologous Prime-Boost Vaccine Strategies for HIV. Dan Barouch April 18, 2012
Novel Heterologous Prime-Boost Vaccine Strategies for HIV Dan Barouch April 18, 2012 Desired Features of a Next Generation HIV-1 Vaccine Candidate The RV1 study suggests that an HIV-1 vaccine is possible
HVTN Laboratory Program: Immunogenicity and Research Assays
HVTN Laboratory Program: Immunogenicity and Research Assays Erica Andersen-Nissen, PhD Director, Cape Town HVTN Immunology Laboratory Considerations for a Pan-African HIV Vaccine Development Agenda Kigali,
GOVX-B11: A Clade B HIV Vaccine for the Developed World
GeoVax Labs, Inc. 19 Lake Park Drive Suite 3 Atlanta, GA 3 (678) 384-72 GOVX-B11: A Clade B HIV Vaccine for the Developed World Executive summary: GOVX-B11 is a Clade B HIV vaccine targeted for use in
HIV and Challenges of Vaccine Development
Dale and Betty Bumpers Vaccine Research Center National Institute of Allergy and Infectious Diseases National Institutes of Health HIV and Challenges of Vaccine Development Richard A. Koup, MD INTEREST
HIV: RV 144 prime boost HIV vaccine efficacy study
HIV: RV 144 prime boost HIV vaccine efficacy study Nelson L. Michael, M.D., Ph.D Colonel, Medical Corps, U.S. Army Director US Military HIV Research Program (MHRP) Walter Reed Army Institute of Research
Long-acting Antivirals Where Are We Headed? Are We Ready? Carl W. Dieffenbach, Ph.D. Director Division of AIDS, NIAID May 3, 2018
Long-acting Antivirals Where Are We Headed? Are We Ready? Carl W. Dieffenbach, Ph.D. Director Division of AIDS, NIAID May 3, 2018 Global HIV Statistics 2017 People living with HIV in 2016 New HIV infections
DNA and Protein Vaccination Confers Protection Upon Mucosal Challenge with Heterologous SIVsmE660 (OA 10.04)
DNA and Protein Vaccination Confers Protection Upon Mucosal Challenge with Heterologous SIVsmE660 (OA 10.04) Rashmi Jalah Human Retrovirus Pathogenesis Section, Vaccine Branch, CCR, National Cancer Institute
A Quarterly Update on HIV Prevention Research. Vol. 8 No. 2
What is it? What could it do? Key Facts Antibodies Passive immunization is the transfer of pre-made antibodies to a person. Passive immunization using today's pre-made antibodies can involve infusion delivered
Current State of HIV Vaccine Development
Current State of HIV Vaccine Development Sandhya Vasan, MD US Military HIV Research Program Henry M. Jackson Foundation Armed Forces Research Institute of Medical Sciences, Bangkok, Thailand AVAC HVAD
Impact of the Proposed Cuts to HIV/AIDS Research. Kevin Fisher AVAC September 7, 2017
Impact of the Proposed Cuts to HIV/AIDS Research Kevin Fisher AVAC September 7, 2017 President s FY18 Budget Cuts $544 m from the FY 2017 NIH HIV/AIDS research budget levels A cut of 18.5% FY 18 Cut FY
Supplementary information. Early development of broad neutralizing antibodies in HIV-1 infected infants
Supplementary information Early development of broad neutralizing antibodies in HIV-1 infected infants Leslie Goo, Vrasha Chohan, Ruth Nduati, Julie Overbaugh Supplementary Figure 1. Neutralization profile
Should There be Further Efficacy Testing of T-T cell Based Vaccines that do not Induce Broadly Neutralizing Antibodies?
Dale and Betty Bumpers Vaccine Research Center National Institute of Allergy and Infectious Diseases National Institutes of Health Department of Health and Human Services Should There be Further Efficacy
Evaluation of lead HIV-1 vaccine regimen in APPROACH:
Evaluation of lead HIV-1 vaccine regimen in : Phase 1/2a study testing heterologous prime boost regimens using mosaic Ad26 and MVA vectors combined with Env protein Hanneke Schuitemaker Martin Freeman,
Combinatorial Vaccines for AIDS and other Infectious Diseases
Dale and Betty Bumpers Vaccine Research Center National Institute of Allergy and Infectious Diseases National Institutes of Health Department of Health and Human Services Combinatorial Vaccines for AIDS
Current Strategies in HIV-1 Vaccine Development Using Replication-Defective Adenovirus as a Case Study
Note: I have added some clarifying comments to the slides -- please click on Comments under View to see them. Current Strategies in HIV-1 Vaccine Development Using Replication-Defective Adenovirus as a
HIV/AIDS: vaccines and alternate strategies for treatment and prevention
Ann. N.Y. Acad. Sci. ISSN 0077-8923 ANNALS OF THE NEW YORK ACADEMY OF SCIENCES Online Meeting Report HIV/AIDS: vaccines and alternate strategies for treatment and prevention Yegor Voronin 1 and Sanjay
HIV Anti-HIV Neutralizing Antibodies
,**/ The Japanese Society for AIDS Research The Journal of AIDS Research : HIV HIV Anti-HIV Neutralizing Antibodies * Junji SHIBATA and Shuzo MATSUSHITA * Division of Clinical Retrovirology and Infectious
Professor Andrew McMichael
BHIVA AUTUMN CONFERENCE 2011 Including CHIVA Parallel Sessions Professor Andrew McMichael University of Oxford 17 18 November 2011, Queen Elizabeth II Conference Centre, London BHIVA AUTUMN CONFERENCE
Third Env Manufacturing Workshop July 20 21, July 20, 2017 Mary Marovich, M.D. Director, Vaccine Research Program
Third Env Manufacturing Workshop July 20 21, 2017 July 20, 2017 Mary Marovich, M.D. Director, Vaccine Research Program Presentation Outline Importance and Impact of an HIV Vaccine DAIDS/VRP Programmatic
4/14/2016. HIV Vaccines and Immunoprotection: Where Are We? Learning Objectives. After attending this presentation, participants will be able to:
HIV Vaccines and Immunoprotection: Where Are We? Mark J. Mulligan, MD, FIDSA Distinguished Professor of Medicine Emory University School of Medicine Atlanta, Georgia FINAL: 04/01/16 Atlanta, Georgia: Friday,
May HIV Vaccines: The Basics
May 2018 HIV Vaccines: The Basics Presentation Overview What is a vaccine? How would an HIV vaccine work? Where are we in the search? What is needed now? What is a Vaccine? A substance that teaches the
Boosts Following Priming with gp120 DNA
Neutralizing Antibody Responses Induced with V3-scaffold Protein Boosts Following Priming with gp120 DNA Susan Zolla-Pazner NYU School of Medicine Problems with Whole Env Immunogens Poor induction of Abs
Advancing HIV Vaccines into Efficacy studies. Glenda Gray WHO PD VAC 7-9 September 2015 Geneva, Switzerland
Advancing HIV Vaccines into Efficacy studies Glenda Gray WHO PD VAC 7-9 September 2015 Geneva, Switzerland What we need to end AIDS: controlling viremia New classes of Drugs Point of care viral load &
Establishment and Targeting of the Viral Reservoir in Rhesus Monkeys
Establishment and Targeting of the Viral Reservoir in Rhesus Monkeys Dan H. Barouch, M.D., Ph.D. Center for Virology and Vaccine Research Beth Israel Deaconess Medical Center Ragon Institute of MGH, MIT,
AIDSVaccine2010 Atlanta, Georgia Willy Bogers. NIH HIVRad Grant nr 5P01AI066287
HIV-1 envelope-cd4 receptor complexes elicit broad T- and B- cell immune responses as well as cross-reactive neutralizing antibodies in Rhesus macaques NIH HIVRad Grant nr 5P01AI066287 AIDSVaccine2010
University of Massachusetts Medical School Matthew R. Costa University of Massachusetts Medical School
University of Massachusetts Medical School escholarship@umms GSBS Dissertations and Theses Graduate School of Biomedical Sciences 10-12-2016 FC Receptor-Mediated Activities of Env-Specific Monoclonal Antibodies
EMERGING ISSUES IN THE HUMORAL IMMUNE RESPONSE TO HIV. (Summary of the recommendations from an Enterprise Working Group)
AIDS Vaccine 07, Seattle, August 20-23, 2007 EMERGING ISSUES IN THE HUMORAL IMMUNE RESPONSE TO HIV (Summary of the recommendations from an Enterprise Working Group) The Working Group Reston, Virginia,
DNA Immunization for HIV Vaccine Development
University of Massachusetts Medical School escholarship@umms GSBS Student Publications Graduate School of Biomedical Sciences 2-25-2014 DNA Immunization for HIV Vaccine Development Yuxin Chen University
24 26 January 2013, Hong Kong SAR, CHINA. TITLE from VIEW and SLIDE MASTER February 27, 2013
The first WHO integrated meeting on development and clinical trials of influenza vaccines that induce broadly protective and long-lasting immune responses 24 26 January 2013, Hong Kong SAR, CHINA 1 TITLE
Review on vectored influenza vaccines. Sarah Gilbert Jenner Institute Oxford
Review on vectored influenza vaccines Sarah Gilbert Jenner Institute Oxford Viral Vectored Influenza Vaccines Can be used to induce antibodies against HA Will also boost CD4 + T cell responses against
NIAID Vaccine Research Center: A Mission to Prevent HIV Infection
NIAID Vaccine Research Center: A Mission to Prevent HIV Infection AIDS Vaccine Awareness Day 20 year anniversary May 18, 2017 Barney S. Graham, MD, PhD Deputy Director Origins of the VRC 1997 1998
Antibody Dependent Cellular Cytotxic activity: Past and Future. Guido Ferrari, M.D. Duke University Medical Center
Antibody Dependent Cellular Cytotxic activity: Past and Future Guido Ferrari, M.D. Duke University Medical Center Mechanism of Antibody Dependent Cellular Cytotoxicity (ADCC) ADCC Effector Cells (NK, monocytes/macrophages,
A Path to an HIV Vaccine: GSID Consortium Activities. Faruk Sinangil, PhD 4th Annual CAVD Meeting Miami, FL December 1-4, 2009
A Path to an HIV Vaccine: GSID Consortium Activities Faruk Sinangil, PhD 4th Annual CAVD Meeting Miami, FL December 1-4, 2009 Project Goals Acquire and disseminate information that will contribute to the
Bispecific Fusion Antibodies. Exhibit 100% Breadth and Picomolar Potency. Craig Pace, PhD
The Aaron Diamond AIDS Research Center Affiliate of The Rockefeller University Bispecific Fusion Antibodies PG9 Ibalizumab & VRC Ibalizumab Exhibit % Breadth and Picomolar Potency Craig Pace, PhD AIDS
Correlates of Immunity: RV144 - Lessons Learned
Correlates of Immunity: RV144 - Lessons Learned US Military HIV Research Program (MHRP) Nelson L. Michael, MD, PhD AIDS Vaccine 2010, Atlanta GA 01 October 2010 Outline RV 144 Correlates Discovery Towards
Ongoing HVTN Trials (Enrolling, In Follow-up, and in Long Term Follow-up)
Ongoing HVTN Trials (, In, and in ) HVTN 085 90 HVTN VRC rad5 multiclade 02/2012 Boston - Brigham; Chicago; Nashville; New York - NYBC; New York - NYBC - Bronx; Philadelphia; Rochester; San Francisco;
HIV An bodies Frequently Cross- React with Intes nal Microbiota An gens. Tony Moody Duke Human Vaccine Ins tute Duke University 8 April 2015
HIV An bodies Frequently Cross- React with Intes nal Microbiota An gens Tony Moody Duke Human Vaccine Ins tute Duke University 8 April 2015 Commensal Bacteria and the Immune System The intes ne is home
TRANS-NIH PLAN FOR HIV RELATED RESEARCH
National Institutes of Health FY 2018 TRANS-NIH PLAN FOR HIV RELATED RESEARCH Prepared by the Office of AIDS Research Maureen M. Goodenow, Ph.D. NIH Associate Director for AIDS Research and Director, Office
HIV Vaccine Clinical Trials at CIDRZ
HIV Vaccine Clinical Trials at CIDRZ Developing a Safe and Effective Vaccine for Prevention of HIV Infections Globally Christine Namakobo Senior Research Nurse Matero Clinical Research Site State of Global
Challenges in Designing HIV Env Immunogens for Developing a Vaccine
b514_chapter-13.qxd 12/4/2007 3:39 PM Page 327 Chapter 13 Challenges in Designing HIV Env Immunogens for Developing a Vaccine Indresh K. Srivastava* and R. Holland Cheng Summary HIV continues to be a major
Future Challenges for Research
Future Challenges for Research HIV Epidemic in Southeastern U.S. Role of the NIH Office of AIDS Research 2nd Annual TN-CFAR Workshop Nashville, TN March 24, 2017 Maureen M. Goodenow, Ph.D. Associate Director
Questions and answers: HVTN 084 vaccine trial
1. What is the HVTN 084 trial? Questions and answers: HVTN 084 vaccine trial Version 2 Last updated December 2, 2010 HVTN 084 is the name of a clinical trial to test the safety of 2 experimental HIV vaccines.
Supplementary Figure 1. ALVAC-protein vaccines and macaque immunization. (A) Maximum likelihood
Supplementary Figure 1. ALVAC-protein vaccines and macaque immunization. (A) Maximum likelihood tree illustrating CRF01_AE gp120 protein sequence relationships between 107 Envs sampled in the RV144 trial
Press conference abstracts Vaccine and Antibody Research Monday, 22 October 2018
Press conference abstracts Vaccine and Antibody Research Monday, 22 October 2018 OA02.05LB Vaccine-induced Gene Signature Correlates with Protection against Acquisition in Three Independent Vaccine Efficacy
HIV cure: current status and implications for the future
HIV cure: current status and implications for the future Carolyn Williamson, PhD Head of Medical Virology, Faculty Health Sciences, University of Cape Town CAPRISA Research Associate, Centre of Excellence
The Collaboration for AIDS Vaccine Discovery. 10th Annual Meeting. Grantee Profiles. December 7 9, 2015 Seattle, Washington
The Collaboration for AIDS Vaccine Discovery 10th Annual Meeting Profiles December 7 9, 2015 Seattle, Washington Table of Contents Ackerman/Alter: Leveraging Antibody Effector Function 4 Alter: A Genetic
Trials & Tribulations: on the way to cure: where do HIV Vaccines fit in? Glenda Gray SA HIV Clinicians Society Conference April, 2016
Trials & Tribulations: on the way to cure: where do HIV Vaccines fit in? Glenda Gray SA HIV Clinicians Society Conference 2016 13-16 April, 2016 Scope Rationale for an HIV vaccine RV144 study in Thailand
In Vivo Electroporation Enhances the Immunogenicity of ADVAX, a DNA-based HIV-1 Vaccine Candidate, in Healthy Volunteers
In Vivo Electroporation Enhances the Immunogenicity of ADVAX, a DNA-based HIV-1 Vaccine Candidate, in Healthy Volunteers Aaron Diamond AIDS Research Center ADVAX Clade B /C DNA Vaccine 8.7 kb 8.2 kb In
HIV Vaccine. Sunee Sirivichayakul, Ph.D. Faculty of Medicine Chulalongkorn University. August 22, 2014
HIV Vaccine Sunee Sirivichayakul, Ph.D. Faculty of Medicine Chulalongkorn University August 22, 2014 Immunity Natural immunity Active natural immunity e.g., infection Passive natural immunity e.g., trans-placental
Safety and Immunogenicity of a Parenterally Administered Rotavirus VP8 Subunit Vaccine in Healthy Adults
Safety and Immunogenicity of a Parenterally Administered Rotavirus VP8 Subunit Vaccine in Healthy Adults Stanley Cryz 1, Clayton Harro 2, Monica McNeal 3, Nicole Meyer 3, Barbara DeNearing 2, Alicia Cage
CROI 2016 Review: Immunology and Vaccines
Frontier AIDS Education and Training Center CROI 2016 Review: Immunology and Vaccines Meena Ramchandani MD MPH Acting Instructor, University of Washington March 2016 This presentation is intended for educational
Isolation of a Broadly Neutralizing Antibody with Low Somatic Mutation from a Chronically Infected HIV-1 Patient
Isolation of a Broadly Neutralizing Antibody with Low Somatic Mutation from a Chronically Infected HIV-1 Patient Amanda Fabra García, Carolina Beltrán Pavez, Alberto Merino Mansilla, Cristina Xufré, Isabel
Update on Biomedical Prevention. Thomas C. Quinn, MD, MSc
Update on Biomedical Prevention Thomas C. Quinn, MD, MSc Associate Director of International Research National Institute of Allergy and Infectious Diseases Director, Johns Hopkins Center for Global Health
Trial Collaborators Start Date* Sites Stage HVTN BMGF IPPOX EuroVacc GSID. HVTN DAIDS GSK Sanofi Jun 2017
Ongoing s:, In, Health/AESI Contact(s) 096/EV04 106 107 108 110 A phase 1 double blind placebo-controlled clinical trial to evaluate the safety and to compare the priming ability of NYVAC alone versus
Letter from the CEO. Dear Friends of IAVI,
IAVI Annual Report 2017 Letter from the CEO Dear Friends of IAVI, We are pleased to present an overview of the progress IAVI and partners have made in 2017 toward our pursuit of the development of vaccines
MHRP. Outline. Is HIV cure possible? HIV persistence. Cure Strategies. Ethical and social considerations. Short video on patients perspectives on cure
Outline Is HIV cure possible? Ø HIV persistence Cure Strategies Ethical and social considerations Short video on patients perspectives on cure A Case of Cure Off ART Treatment Mechanism Lesson The Berlin
The Third D: Long Term Solutions to End the Epidemic. Mitchell Warren Executive Director, AVAC 12 February 2014
The Third D: Long Term Solutions to End the Epidemic Mitchell Warren Executive Director, AVAC 12 February 2014 Key clinical trial milestones: HIV vaccine research First HIV vaccine trial opens Phase
Alabama Vaccine Research Clinic. Clinical Research Trials Guide: Vaccines & Microbicides. University of Alabama at Birmingham
Alabama Vaccine Research Clinic Clinical Research Trials Guide: Vaccines & Microbicides University of Alabama at Birmingham Introduction About the AVRC Since 1994, the Alabama Vaccine Research Clinic (AVRC)
We are IntechOpen, the first native scientific publisher of Open Access books. International authors and editors. Our authors are among the TOP 1%
We are IntechOpen, the first native scientific publisher of Open Access books 3,350 108,000 1.7 M Open access books available International authors and editors Downloads Our authors are among the 151 Countries
Overview of the Joint HVTN/HPTN Research Portfolio. Theresa Gamble, PhD HPTN LOC May 15, 2018
Overview of the Joint HVTN/HPTN Research Portfolio Theresa Gamble, PhD HPTN LOC May 15, 2018 1 Joint HVTN/HPTN mab Portfolio HVTN 130/HPTN 089 HVTN 703/HPTN 081 HVTN 704/HPTN 084 AMP (VRC01) HVTN 127/HPTN
Adjuvant-Specific Serum Cytokine Profiles in the Context of a DNA Prime-Protein Boost HIV-1 Vaccine: A Dissertation
University of Massachusetts Medical School escholarship@umms GSBS Dissertations and Theses Graduate School of Biomedical Sciences 4-29-2013 Adjuvant-Specific Serum Cytokine Profiles in the Context of a
State of the ART: HIV Cure where are we now and. where are we going? Jintanat Ananworanich, MD, PhD MHRP
State of the ART: HIV Cure where are we now and ì where are we going? Jintanat Ananworanich, MD, PhD Associate Director for Therapeu1cs Research US Military HIV Research Program (MHRP) Maryland, USA Deputy
December 14, Letter of Amendment 1 Version 2.0 HVTN 704/HPTN 085
December 14, 2016 Letter of Amendment 1 Version 2.0 HVTN 704/HPTN 085 A phase 2b study to evaluate the safety and efficacy of VRC01 broadly neutralizing monoclonal antibody in reducing acquisition of HIV-1
Planned Vaccine Trials to Follow-up on RV 144. Merlin Robb, MD Deputy Director for Clinical Research MHRP
Planned Vaccine Trials to Follow-up on RV 144 Merlin Robb, MD Deputy Director for Clinical Research MHRP Planned studies are mutually reinforcing and will amplify public health impact and regional relevance
Case study of formulating two Subtype C gp120 proteins
Case study of formulating two Subtype C gp120 proteins Antu Dey, DPhil. Senior Director, IAVI (formerly at GSK Vaccines) Associate Project Leader HIV Research Head Formulation Sciences & Process Development
Maternal, Adolescent, and Pediatric HIV/AIDS Therapeutics Clinical Trials Network:
Maternal, Adolescent, and Pediatric HIV/AIDS Therapeutics Clinical Trials Network: Pregnant Women in the NIAID HIV/AIDS Clinical Trials Network Recompetition Carl W. Dieffenbach, Ph.D. Director Division
Comments made today contain forward looking statements as described under the Private Securities Litigation Reform Act of Our forward looking
EBOLA HIV January 2015 Comments made today contain forward looking statements as described under the Private Securities Litigation Reform Act of 1995. Our forward looking statements represent our current
Richard A. Jenkins PhD Prevention Research Branch, NIDA July 19, 2017 Fordham University
Richard A. Jenkins PhD Prevention Research Branch, NIDA jenkinsri@mail.nih.gov July 19, 2017 Fordham University So, what s the next step An efficacy-type trial (R01)? A pilot intervention trial (R34)?
Crystallization-grade After D After V3 cocktail. Time (s) Time (s) Time (s) Time (s) Time (s) Time (s)
Ligand Type Name 6 Crystallization-grade After 447-52D After V3 cocktail Receptor CD4 Resonance Units 5 1 5 1 5 1 Broadly neutralizing antibodies 2G12 VRC26.9 Resonance Units Resonance Units 3 1 15 1 5
Universal Influenza Vaccine Development
Dale and Betty Bumpers Vaccine Research Center National Institute of Allergy and Infectious Diseases National Institutes of Health Universal Influenza Vaccine Development 2016 Global Vaccine and Immunization
Ebola Vaccines and Vaccination
Ebola Vaccines and Vaccination Report of the SAGE Working Group on Ebola Vaccines and Vaccination with provisional recommendations for vaccination September 30, 2015 SECTION C: CONCLUSIONS AND RECOMMENDATIONS
Development of a Recombinant Subunit Dengue Vaccine. Flavivirus Vaccination Fondation Mérieux December 8, 2010 Beth-Ann Coller
Development of a Recombinant Subunit Dengue Vaccine Flavivirus Vaccination Fondation Mérieux December 8, 2010 Beth-Ann Coller Recombinant Subunit Dengue Vaccine Recombinant Envelope Protein Vaccine Hawaii
TOWARDS A UNIVERSAL INFLUENZA VIRUS VACCINE
TOWARDS A UNIVERSAL INFLUENZA VIRUS VACCINE Peter Palese Icahn School of Medicine at Mount Sinai New York OPTIONS IX 8-26-16 ISIRV - Options IX for the Control of Influenza Peter Palese, PhD Professor
Clinical Trials of Pandemic Vaccines: Key Issues. John Treanor University of Rochester Rochester, NY
Clinical Trials of Pandemic Vaccines: Key Issues John Treanor University of Rochester Rochester, NY Inactivated vaccine approach Proven technology Used successfully in 1957 and 1968 Abundant efficacy data
Heterologous Tier 1 R5 SHIV-C Challenges: Correlates of Protection
Heterologous Tier 1 R5 SHIV-C Challenges: Correlates of Protection Enterprise Meeting: The Appropriate Use of Tiered Virus Panels when Assessing HIV-1 Vaccine-elicited Neutralizing Antibodies" July 7 th,
Development of a Universal T Cell Vaccine. Tomáš Hanke Weatherall Institute of Molecular Medicine University of Oxford United Kingdom
Development of a Universal T Cell Vaccine Tomáš Hanke Weatherall Institute of Molecular Medicine University of Oxford United Kingdom Development of HIV-1 vaccines Induction of cell-mediated responses Immunogens
What is the place of the monoclonal antibodies in the clinic?
What is the place of the monoclonal antibodies in the clinic? Dr Julià Blanco 2018/04/26 DISCLOSURE AlbaJuna Therapeutics, S.L. ANTIBODIES IN HIV INFECTION. ANTIVIRAL (NEUTRALIZING) ACTIVITY env THE BROADLY
The humoral immune responses to IBV proteins.
The humoral immune responses to IBV proteins. E. Dan Heller and Rosa Meir The Hebrew University of Jerusalem, Israel COST FA1207 meeting WG2 + WG3, Budapest, Jan. 2015 1 IBV encodes four major structural
The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters
Antibody Responses After Analytic Treatment Interruption in Human Immunodeficiency Virus-1- Infected Individuals on Early Initiated Antiretroviral Therapy The Harvard community has made this article openly
The History of HIV Vaccine Development
The History of HIV Vaccine Development a short story on 30 years of research å Dr. Jill Gilmour International AIDS Vaccine Initiative Barcelona, 6 October 2013 IAVI is a product-development partnership
Development of prophylactic vaccines against HIV-1
Schiffner et al. Retrovirology 2013, 10:72 REVIEW Open Access Development of prophylactic vaccines against HIV-1 Torben Schiffner 1, Quentin J Sattentau 1* and Lucy Dorrell 2,3 Abstract The focus of most
Are we targeting the right HIV determinants?
QuickTime et un décompresseur TIFF (non compressé) sont requis pour visionner cette image. AIDS Vaccine 2009 October 22 nd 2009 - Paris Are we targeting the right HIV determinants? Françoise BARRÉ-SINOUSSI
NIH Public Access Author Manuscript Nature. Author manuscript; available in PMC 2009 July 1.
NIH Public Access Author Manuscript Published in final edited form as: Nature. 2009 January 1; 457(7225): 87 91. doi:10.1038/nature07469. Immune Control of an SIV Challenge by a T Cell-Based Vaccine in
Generation of Robust Antibody Responses to HIV-1 MPER Antigens in Mice Reconstituted with Cultured B cells
Generation of Robust Antibody Responses to HIV-1 MPER Antigens in Mice Reconstituted with Cultured B cells T. Matt Holl 1, Masayuki Kuraoka 1, Dongmei Liao 1, Laurent Verkoczy 2, M. Anthony Moody 2, Munir
A global approach to HIV-1 vaccine development
A global approach to HIV-1 vaccine development The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters. Citation Published Version Accessed
NIH Public Access Author Manuscript Nat Med. Author manuscript; available in PMC 2010 September 1.
NIH Public Access Author Manuscript Published in final edited form as: Nat Med. 2010 March ; 16(3): 319 323. doi:10.1038/nm.2089. Mosaic HIV-1 Vaccines Expand the Breadth and Depth of Cellular Immune Responses
A centralized gene-based HIV-1 vaccine elicits broad cross-clade cellular immune responses in rhesus monkeys
A centralized gene-based HIV-1 vaccine elicits broad cross-clade cellular immune responses in rhesus monkeys Sampa Santra, Bette T. Korber, Mark Muldoon, Dan H. Barouch, Gary J. Nabel, Feng Gao, Beatrice
University of Massachusetts Medical School Michael Vaine University of Massachusetts Medical School
University of Massachusetts Medical School escholarship@umms GSBS Student Publications Graduate School of Biomedical Sciences 8-23-2008 Improved induction of antibodies against key neutralizing epitopes
Spike Trimer RNA. dsdna
Spike Trimer RNA dsdna Spike Trimer RNA Spike trimer subunits xxx gp120: receptor and coreceptor binding xxxxxxx gp41: membrane anchoring and target cell fusion dsdna Spike Trimer HIV gp120 binds to host
HIV-specific humoral responses benefit from stronger prime in phase Ib clinical trial
The Journal of Clinical Investigation Clinical Medicine HIV-specific humoral responses benefit from stronger prime in phase Ib clinical trial Pierre-Alexandre Bart, 1,2,11 Yunda Huang, 3,11 Shelly T. Karuna,